Industry Reports

Custom Research

About

Knowledge Center

Contact

Generic Drugs Market Assessment, By Application [Neurovascular, Cardiovascular, Dermatology, Oncology, Respiratory, Diabetology and Others], By Type [Biosimilar Generics, Small Molecule Generics], By Brand [Branded Generic, Pure Generic], By Route of Administration [Oral, Injectable, Topical and Others], By Distribution Channel [Hospital Pharmacy, Retail Pharmacy, Online Pharmacy], By Region, Opportunities, and Forecast, 2016-2030F

Q: What is the market size and growth rate of the Global Generic Drugs Market?

The global generic drugs market size was valued at USD 335.65 billion in 2022 which is expected to grow to USD 7.06 billion in 2030 with a CAGR of 582.76% during the forecast period between 2023 and 2030.

Q: What are the major drivers influencing the growth of global generic drugs market?

Increasing number of patients with chronic diseases, increasing geriatric population, technological advancements, government initiatives and rising healthcare cost are driving the market for generic drugs.

Q: What are the regions covered in the final report for Global Generic Drugs Market?

The market is thoroughly studied after segmenting global into North America, Europe, South America, Asia-Pacific, Middle East and Africa.

Q: Who are the key players operating in Global Generic Drugs Market?

The key players operating in global generic drugs market are Viatris, Hikma Pharmaceuticals, Novartis AG, Teva Pharmaceuticals, Fresenius SE & Co. KGaA., Sun Pharmaceutical Industries Ltd., Cipla, Aspen Holdings, Aurobindo Pharmaceuticals, Dr. Reddy's Laboratories, Lupin.

Generic Drugs market size was estimated at USD 335.65 billion in 2022 and is projected to reach USD 582.76 billion in 2030, growing at a CAGR of 7.06% for the forecast period between 2023 and 2030.

Home>Industry Reports>Generic Drugs Market Assessment, Opportunities, and Forecast, 2016-2030F

The Global Generic Drugs market size was estimated at USD 335.65 billion in 2022 and is projected to reach USD 582.76 billion in 2030, growing at a CAGR of 7.06% for the forecast period between 2023 and 2030. Multiple factors contributing to the growth of the global generic drugs market are increasing number of patients with chronic diseases, rising geriatric population, technological advancements, government initiatives and rising healthcare costs are driving the demand for generic drugs.

Generic drugs are becoming increasingly popular in both developed and developing countries because they are less expensive and reduces dependency on multinational pharmaceutical companies for developing drugs because it requires less investment to make copies of these drugs after obtaining the patent holder's permission. As the patents of branded drugs are expiring, the global market for generic drugs will expand rapidly. Favorable policies in various nations that aim to lower overall healthcare costs and minimize the spread of chronic diseases are facilitating growth. Although, factors such as stringent regulations, quality issues and decreasing profit margin are some of the factors that can hinder the growth of global generic drugs market.

Increasing Prevalence of Chronic Diseases and Geriatric Population

The increasing prevalence of chronic diseases and the growth of the geriatric population are two significant factors that have a substantial impact on the global generic drugs market. Chronic diseases such as cardiovascular, neurological, diabetes, and respiratory conditions are becoming increasingly common worldwide due to several factors, including changes in lifestyle, aging population, and environmental factors. By 2060, a projected 48 million individuals (47% of all fatalities worldwide) are estimated to lose life due to serious health-related suffering, an 87% increase from 26 million in 2016. 83% of these casualties are expected to take place in low- and middle-income nations.

Cardiovascular Drugs Contributes to Major Market Share

Cardiovascular generic drugs contributed one-third of the total market share in 2022, globally. As per World Health Organization (WHO), cardiovascular diseases are the major cause of the global mortality rate marking nearly 17.9 million deaths per year worldwide. Heart attacks and strokes account for over 80% of cardiovascular deaths, with about a third of these fatalities happening prematurely among individuals below the age of 70 years. An unhealthy diet, physical inactivity, consumption of tobacco, and excessive alcohol consumption are the primary behavioral factors that significantly contribute to heart disease and stroke. These behaviors can lead to elevated blood pressure, increased blood glucose levels, elevated blood lipids, as well as overweight and obesity, manifesting as potential effects of these risk factors on individuals.

Oral Drugs Being the Most Preferred Route of Administration

The oral generic drug segment held two-thirds of the market share in 2022 globally. Among the different methods of drug delivery, oral administration is preferred over injectable due to its numerous advantages. These benefits encompass safety, high patient adherence, easy ingestion, avoidance of pain, and the ability to accommodate a wide range of medications, making it a versatile option. Hetero, a pharmaceutical company based in Hyderabad, India, declared in 2022 that its generic form of the COVID-19 oral antiviral treatment candidate nirmatrelvir had obtained approval from the World Health Organization Prequalification of Medicines Program (WHO PQ).

Technological Advancements

With the advent of RPA (Robotic Process Automation) and AI in the pharmaceutical industry, automation has helped in overcoming difficulties and improving efficiency. RPA and AI aid in increasing productivity, lowering costs, and improving performance. Through automation, these technologies also assure regulatory compliance within an organization's process. Artificial intelligence, machine learning and natural language processing are being used extensively in research and development of pharmaceutical drugs. Predictive analytics and natural language processing are used to scan databases of brand name medicine compounds for similar compounds that scientists can use to develop generic drugs. Machine learning is used to determine a compound's solubility in order to ensure that it retains its effectiveness over time.

Government Initiatives

Governments in developed countries are making efforts to reduce healthcare costs by promoting the manufacturing of generic drugs. On the other hand, healthcare industries in developing countries are affected by issues like affordability and accessibility. In the United States, the Food and Drug Administration (FDA) has taken various steps to expedite the approval process for generic drugs, including the Generic Drug User Fee Amendments (GDUFA) program, which aims to speed up the review of generic drug applications. In the European Union, the European Medicines Agency (EMA) has also implemented initiatives to streamline the approval process for generic drugs, such as the generic medicines work-sharing initiative, which allows regulators from different countries to work together to assess the safety and efficacy of generic medicines. Overall, these initiatives by governments around the world are helping to increase the availability and affordability of generic drugs, thereby improving access to healthcare for patients.

Impact of COVID-19

The COVID-19 pandemic had a short-term and long-term impact on the pharmaceutical sector. Short term impacts such as demand change, panic buying, supply shortage of API (active pharmaceutical ingredient) and finished products. Long term impacts such as delayed approvals for non-COVID-related pharmaceutical products, ethical considerations, and consumption trend changes in health-related products. Supply chain was one of the major factors that impacted the generic drugs market, many countries rely on India and China to produce generic drugs, and the pandemic led to disruptions in the production and distribution of drugs due to factory closures and supply chain disruptions.

The pandemic also led to increase in demand for certain generic drugs, particularly those used to treat COVID-19 symptoms such as fever and respiratory distress, which led to shortages of these drugs in some regions and price hikes. Furthermore, the pandemic has also highlighted the importance of investing in research and development for new generic drugs, particularly for COVID-19 treatments and vaccines.

Impact of Russia-Ukraine War

Russia’s invasion of Ukraine affected millions of people, not just in Eastern Europe nations but throughout the world. Drug developers experienced development delays, lost business continuity, and the threat of noncompliance for on-market drugs. Drugmakers such as Novartis, AbbVie, Eli Lilly and hundreds of companies announced a pause or withdrawal of business in Russia. The Director General of Pharmexcil (Pharmaceutical Export Promotion Council of India) expressed concerns about Indian pharmaceutical exports losing ground in the CIS (Commonwealth of Independent States). He also expressed that India might lose a few millions in terms of exports to CIS and Russia, since Russia is one of the top five exporting destinations of India and Ukraine is the third largest exporter of pharmaceuticals for India. Indian drug companies such as Dr Reddy’s Laboratories and Sun Pharma have strong presence in Ukraine and Russia.

Global Generic Drugs Market: Report Scope

Global Generic Drugs Market Assessment, Opportunities and Forecast, 2016-2030F”, is a comprehensive report by Markets & Data, providing in-depth analysis and qualitative & quantitative assessment of the current state of the generic drugs market globally, industry dynamics and challenges. The report includes market size, segmental shares, growth trends, COVID-19 and Russia-Ukraine war impact, opportunities and forecast between 2023 and 2030. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Report Attribute	Details
Base Year of the Analysis	2022
Historical Period	2016-2021
Forecast Period	2022-2030
Projected Growth Rate	CAGR of 7.06% between 2023 and 2030
Revenue Forecast in 2030	USD 582.76 Billion
Units	Revenue in USD Billion
Segments Covered	By Application, By Type, By Brand, By Route of Administration, By Distribution Channel, By Region
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profiled	Viatris, Hikma Pharmaceuticals, Novartis AG, Teva Pharmaceuticals, Fresenius SE & Co. KGaA., Sun Pharmaceutical Industries Ltd., Cipla, Aspen Holdings, Aurobindo Pharmaceuticals, Dr. Reddy's Laboratories, Lupin
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfil your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In this report, Global Generic Drugs Market has been segmented into the following categories:

1. By Application

1.1 Neurovascular

1.2 Cardiovascular

1.3 Dermatology

1.4 Oncology

1.5 Diabetology

1.6 Respiratory

1.7 Others

2. By Type

2.1 Biosimilar Generics

2.2 Small Molecule Generics

3. By Brand

3.1 Branded Generic

3.2 Pure Generic

4. By Route of Administration

4.1 Oral

4.2 Injectable

4.3 Topical

4.4 Others

5. By Distribution Channel

5.1 Hospital Pharmacy

5.2 Retail Pharmacy

5.3 Online Pharmacy

6. By Region

6.1 North America

6.2 Europe

6.3 Asia Pacific

6.4 South America

6.5 Middle East and Africa

Key Players Landscape and Outlook

The Global Generic Drugs market is dominated by Viatris, Hikma Pharmaceuticals, Novartis AG, Teva Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Cipla, Dr. Reddy's Laboratories, Lupin and many others.
In March 2023, MPP (Medicines Patent Pool), a United Nations-supported public health organisation, announced that it has entered into sublicensing agreements with three drug companies-Aurobindo Pharma, Cipla, and Viatris- for the manufacturing of generic variants of ViiV Healthcare's long-acting HIV prevention medicine. According to the agreement, the organizations would produce the generic version of the medication in India, with Cipla also planning to produce the drug in South Africa.
Sun Pharma recalled more than 34,000 bottles of Diltiazem Hydrochloride; a generic drug used to treat high blood pressure in US due to manufacturing issues.

Key Players Operating in Global Generic Drugs Market

· Viatris

· Hikma Pharmaceuticals

· Novartis AG

· Teva Pharmaceuticals

· Fresenius SE & Co. KGaA.

· Sun Pharmaceutical

· Cipla

· Aspen Holdings

· Aurobindo Pharmaceuticals

· Dr. Reddy's Laboratories

· Lupin

If you can't find what you're searching for or have any custom requirements for Global Generic Drugs Market, you may approach our team at info@marketsandata.com

Table of Content

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19

4. Impact of Russia-Ukraine War

5. Executive Summary

6. Global Generic Drug Market Outlook, 2016-2030F

6.1. Market Size & Forecast

6.1.1.By Value

6.1.2.By Volume

6.2. By Application

6.2.1.Neurovascular

6.2.2.Cardiovascular

6.2.3.Dermatology

6.2.4.Oncology

6.2.5.Diabetology

6.2.6.Respiratory

6.2.7.Others

6.3. By Type

6.3.1.Biosimilar Generics

6.3.2.Small Molecule Generics

6.4. By Brand

6.4.1.Branded Generic

6.4.2.Pure Generic

6.5. By Route of Administration

6.5.1.Oral

6.5.2.Injectable

6.5.3.Topical

6.5.4.Others

6.6. By Distribution Channel

6.6.1.Hospital Pharmacy

6.6.2.Retail Pharmacy

6.6.3.Online Pharmacy

6.7. By Region

6.7.1.North America

6.7.2.Europe

6.7.3.Asia Pacific

6.7.4.South America

6.7.5.Middle East and Africa

6.8. By Company Market Share (%), 2022

7. Global Generic Drug Market Outlook, By Region, 2016-2030F

7.1. North America*

7.1.1.By Application

7.1.1.1. Neurovascular

7.1.1.2. Cardiovascular

7.1.1.3. Dermatology

7.1.1.4. Oncology

7.1.1.5. Diabetology

7.1.1.6. Respiratory

7.1.1.7. Others

7.1.2.By Type

7.1.2.1. Biosimilar Generics

7.1.2.2. Small Molecule Generics

7.1.3.By Brand

7.1.3.1. Branded Generic

7.1.3.2. Pure Generic

7.1.4.By Route of Administration

7.1.4.1. Oral

7.1.4.2. Injectable

7.1.4.3. Topical

7.1.4.4. Others

7.1.5.By Distribution Channel

7.1.5.1. Hospital Pharmacy

7.1.5.2. Retail Pharmacy

7.1.5.3. Online Pharmacy

7.1.6.United States*

7.1.6.1. By Application

7.1.6.1.1. Neurovascular

7.1.6.1.2. Cardiovascular

7.1.6.1.3. Dermatology

7.1.6.1.4. Oncology

7.1.6.1.5. Diabetology

7.1.6.1.6. Respiratory

7.1.6.1.7. Others

7.1.6.2. By Type

7.1.6.2.1. Biosimilar Generics

7.1.6.2.2. Small Molecule Generics

7.1.6.3. By Brand

7.1.6.3.1. Branded Generic

7.1.6.3.2. Pure Generic

7.1.6.4. By Route of Administration

7.1.6.4.1. Oral

7.1.6.4.2. Injectable

7.1.6.4.3. Topical

7.1.6.4.4. Others

7.1.6.5. By Distribution Channel

7.1.6.5.1. Hospital Pharmacy

7.1.6.5.2. Retail Pharmacy

7.1.6.5.3. Online Pharmacy

7.1.7.Canada

7.1.8.Mexico

*All segments will be provided for all regions and countries covered

7.1 Europe

7.1.1 Germany

7.1.2 France

7.1.3 Italy

7.1.4 United Kingdom

7.1.5 Spain

7.2 South America

7.2.1 Brazil

7.2.2 Argentina

7.2.3 Colombia

7.2.4 Chile

7.3 Asia-Pacific

7.3.1 India

7.3.2 China

7.3.3 Japan

7.3.4 Australia

7.3.5 Thailand

7.3.6 South Korea

7.3.7 Singapore

7.3.8 Malaysia

7.3.9 Indonesia

7.3.10 Philippines

7.4 Middle East & Africa

7.4.1 Saudi Arabia

7.4.2 UAE

7.4.3 South Africa

7.4.4 Egypt

7.4.5 Algeria

8 Market Mapping, 2022

8.1 By Application

8.2 By Type

8.3 By Brand

8.4 By Route of Administration

8.5 By Distribution Channel

8.6 By Region

9 Macro Environment and Industry Structure

9.1 Supply Demand Analysis

9.2 Import Export Analysis – Volume and Value

9.3 Supply/Value Chain Analysis

9.4 PESTEL Analysis

9.4.1 Political Factors

9.4.2 Economic System

9.4.3 Social Implications

9.4.4 Technological Advancements

9.4.5 Environmental Impacts

9.4.6 Legal Compliances and Regulatory Policies (Statutory Bodies Included)

9.5 Porter’s Five Forces Analysis

9.5.1 Supplier Power

9.5.2 Buyer Power

9.5.3 Substitution Threat

9.5.4 Threat from New Entrant

9.5.5 Competitive Rivalry

10 Regulatory Framework and Innovation

10.1 Clinical Trials

10.2 Patent Landscape

10.3 Regulatory Approvals

10.4 Innovations/Emerging Technologies

11 Market Dynamics

11.1 Growth Drivers

11.2 Growth Inhibitors (Challenges, Restraints)

12 Key Players Landscape

12.1 Competition Matrix of Top Five Market Leaders

12.2 Market Revenue Analysis of Top Five Market Leaders (in %, 2022)

12.3 Mergers and Acquisitions/Joint Ventures (If Applicable)

12.4 SWOT Analysis (For Five Market Players)

12.5 Patent Analysis (If Applicable)

13 Pricing Analysis

14 Case Studies

15 Key Players Outlook

15.1 Viatris

15.1.1 Company Details

15.1.2 Key Management Personnel

15.1.3 Products & Services

15.1.4 Financials (As reported)

15.1.5 Key Market Focus & Geographical Presence

15.1.6 Recent Developments

15.2 Hikma Pharmaceuticals

15.3 Novartis AG

15.4 Teva Pharmaceuticals Industries Ltd.

15.5 Fresenius SE & Co. KGaA.

15.6 Sun Pharmaceutical Industries Ltd.

15.7 Cipla

15.8 Aspen Holdings

15.9 Aurobindo Pharmaceuticals

15.10 Dr. Reddy's Laboratories

15.11 Lupin

15.12 Others

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

16 Strategic Recommendations

17 About Us & Disclaimer

List of Figure-Global Generic Drug Market

Figure 1. Global Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 2. Global Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 3. Global Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 4. Global Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 5. Global Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 6. Global Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 7. Global Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 8. Global Generic Drug Market Share, By Region, in USD Billion, 2016-2030F

Figure 9. North America Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 10. North America Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 11. North America Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 12. North America Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 13. North America Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 14. North America Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 15. North America Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 16. North America Generic Drug Market Share, By Country, in USD Billion, 2016-2030F

Figure 17. United States Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 18. United States Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 19. United States Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 20. United States Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 21. United States Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 22. United States Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 23. United States Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 24. Canada Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 25. Canada Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 26. Canada Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 27. Canada Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 28. Canada Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 29. Canada Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 30. Canada Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 31. Mexico Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 32. Mexico Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 33. Mexico Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 34. Mexico Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 35. Mexico Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 36. Mexico Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 37. Mexico Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 38. Europe Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 39. Europe Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 40. Europe Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 41. Europe Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 42. Europe Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 43. Europe Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 44. Europe Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 45. Europe Generic Drug Market Share, By Country, in USD Billion, 2016-2030F

Figure 46. Germany Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 47. Germany Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 48. Germany Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 49. Germany Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 50. Germany Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 51. Germany Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 52. Germany Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 53. France Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 54. France Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 55. France Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 56. France Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 57. France Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 58. France Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 59. France Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 60. Italy Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 61. Italy Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 62. Italy Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 63. Italy Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 64. Italy Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 65. Italy Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 66. Italy Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 67. United Kingdom Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 68. United Kingdom Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 69. United Kingdom Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 70. United Kingdom Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 71. United Kingdom Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 72. United Kingdom Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 73. United Kingdom Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 74. Spain Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 75. Spain Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 76. Spain Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 77. Spain Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 78. Spain Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 79. Spain Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 80. Spain Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 81. South America Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 82. South America Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 83. South America Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 84. South America Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 85. South America Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 86. South America Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 87. South America Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 88. South America Generic Drug Market Share, By Country, in USD Billion, 2016-2030F

Figure 89. Brazil Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 90. Brazil Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 91. Brazil Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 92. Brazil Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 93. Brazil Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 94. Brazil Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 95. Brazil Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 96. Argentina Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 97. Argentina Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 98. Argentina Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 99. Argentina Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 100. Argentina Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 101. Argentina Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 102. Argentina Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 103. Colombia Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 104. Colombia Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 105. Colombia Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 106. Colombia Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 107. Colombia Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 108. Colombia Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 109. Colombia Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 110. Chile Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 111. Chile Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 112. Chile Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 113. Chile Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 114. Chile Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 115. Chile Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 116. Chile Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 117. Asia-Pacific Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 118. Asia-Pacific Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 119. Asia-Pacific Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 120. Asia-Pacific Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 121. Asia-Pacific Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 122. Asia-Pacific Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 123. Asia- Pacific Cream Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 124. Asia-Pacific Generic Drug Market Share, By Country, in USD Billion, 2016-2030F

Figure 125. India Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 126. India Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 127. India Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 128. India Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 129. India Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 130. India Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 131. India Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 132. China Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 133. China Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 134. China Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 135. China Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 136. China Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 137. China Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 138. China Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 139. Japan Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 140. Japan Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 141. Japan Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 142. Japan Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 143. Japan Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 144. Japan Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 145. Japan Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 146. Australia Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 147. Australia Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 148. Australia Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 149. Australia Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 150. Australia Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 151. Australia Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 152. Australia Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 153. Thailand Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 154. Thailand Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 155. Thailand Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 156. Thailand Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 157. Thailand Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 158. Thailand Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 159. Thailand Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 160. South Korea Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 161. South Korea Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 162. South Korea Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 163. South Korea Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 164. South Korea Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 165. South Korea Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 166. South Korea Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 167. Singapore Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 168. Singapore Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 169. Singapore Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 170. Singapore Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 171. Singapore Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 172. Singapore Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 173. Singapore Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 174. Malaysia Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 175. Malaysia Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 176. Malaysia Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 177. Malaysia Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 178. Malaysia Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 179. Malaysia Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 180. Malaysia Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 181. Indonesia Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 182. Indonesia Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 183. Indonesia Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 184. Indonesia Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 185. Indonesia Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 186. Indonesia Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 187. Indonesia Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 188. Philippines Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 189. Philippines Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 190. Philippines Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 191. Philippines Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 192. Philippines Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 193. Philippines Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 194. Philippines Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 195. Middle East & Africa Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 196. Middle East & Africa Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 197. Middle East & Africa Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 198. Middle East & Africa Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 199. Middle East & Africa Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 200. Middle East & Africa Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 201. Middle East & Africa Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 202. Middle East & Africa Generic Drug Market Share, By Country, in USD Billion, 2016-2030F

Figure 203. Saudi Arabia Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 204. Saudi Arabia Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 205. Saudi Arabia Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 206. Saudi Arabia Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 207. Saudi Arabia Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 208. Saudi Arabia Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 209. Saudi Arabia Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 210. UAE Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 211. UAE Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 212. UAE Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 213. UAE Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 214. UAE Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 215. UAE Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 216. UAE Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 217. South Africa Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 218. South Africa Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 219. South Africa Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 220. South Africa Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 221. South Africa Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 222. South Africa Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 223. South Africa Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 224. Egypt Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 225. Egypt Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 226. Egypt Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 227. Egypt Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 228. Egypt Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 229. Egypt Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 230. Egypt Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 231. Algeria Generic Drug Market, By Value, in USD Billion, 2016-2030F

Figure 232. Alegria Generic Drug Market, By Volume, in Unit Thousand, 2016-2030F

Figure 233. Algeria Generic Drug Market Share, By Application, in USD Billion, 2016-2030F

Figure 234. Algeria Generic Drug Market Share, By Type, in USD Billion, 2016-2030F

Figure 235. Algeria Generic Drug Market Share, By Brand, in USD Billion, 2016-2030F

Figure 236. Algeria Generic Drug Market Share, By Route of Administration, in USD Billion, 2016-2030F

Figure 237. Algeria Generic Drug Market Share, By Distribution Channel, in USD Billion, 2016-2030F

Figure 238. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 239. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 240. By Brand Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 241. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 242. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 243. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022

List of Table-Global Generic Drug Market

Table 1. Pricing Analysis of Applications from Key Players

Table 2. Competition Matrix of Top 5 Market Leaders

Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)

Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

Frequently Asked Questions

What is the market size and growth rate of the Global Generic Drugs Market?

What are the major drivers influencing the growth of global generic drugs market?

What are the regions covered in the final report for Global Generic Drugs Market?

Who are the key players operating in Global Generic Drugs Market?

See Related Reports

View ALL

Global Tyre Market Opportunities and Forecast, 2016-2030F

Global Tyre Market size was valued at USD 261.29 billion in 2022, which is expected to reach USD 425.81 billion in 2030 with a CAGR of 6.15% for the forecast period between 2023 and 2030. ....Read More

Published on

December 2023

6,950

Japan Artificial Intelligence Market Assessment, Opportunities, and Forecast, FY2017-FY2031F

Japan's Artificial Intelligence market has been witnessing notable progress. The Japan Artificial Intelligence market is estimated to achieve a value of USD 15.84 billion by the fiscal year 2031, showing substantial growth from USD 5.95 billion in FY....Read More

Published on

December 2023

3,300

Vietnam Commercial Vehicle Market Assessment, Opportunities and Forecast, 2016-2030F

Vietnam Commercial Vehicle Market size was valued at USD 3.07 billion in 2022 which is expected to reach USD 5.84 billion in 2030 with a CAGR of 8.37% for the forecast period between 2023 and 2030. ....Read More

Published on

December 2023

3,300

Japan Internet of Things Market Assessment, Opportunities and Forecast, FY2017-FY2031

Japan Internet of Things Market size is valued at USD 11.71 billion in FY2023, expected to reach USD 50.08 billion in FY2031 with a CAGR of 19.92% for the forecast period between FY2024 and FY2031.....Read More

Published on

December 2023

3,300

Purchase Options

USD ($)